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LETTER TO THE EDITOR
Appropriate Use of Quality Measures: Response to ‘‘Risk Factors for
Hospital Readmission Within 30 Days: A New Quality Measure for
Children With Sickle Cell Disease’’
To the Editor: The recent article, ‘‘Risk Factors for Hospital
Readmission Within 30 Days: A New Quality Measure for Children
with Sickle Cell Disease’’ by Frei-Jones et al. [1] and Highlight by
Quinn [2] raise important considerations for identifying risk factors
and valid quality measures for children with SCD. We agree with the
concerns raised and would like to correct a misunderstanding
regarding what is described as a ‘‘new quality measure’’ issued as an
‘‘edict by NACHRI.’’
It is important to consider the origin and intended use of the
30-day readmission measure for SCD, which is neither new nor
decreed. The authors are correct that the measure was ‘‘originally
developed as an ORYX non-core measure,’’ proposed by the
National Association of Children’s Hospitals and Related Institu-
tions (NACHRI) in 1996 in response to the Joint Commission’s
(TJC) call for Performance Measurement Systems in TJC’s quest to
integrate performance measurement into the accreditation process.
As TJC rolled out its ORYX requirements, this measure was one of
many available to hospitals serving children.
Approximately 80 of NACHRI’s 216 member hospitals submit
inpatient discharge abstract data to an aggregate data base, which
they use to look at their own case mix and utilization data as well as
aggregate data from other institutions. Because some hospitals were
already submitting data through NACHRI and because of the
relative dearth of measures for pediatric care, several member
hospitals worked with NACHRI to identify six initial performance
measures that could be generated through this system without
additional data collection. Selection of the 30-day readmission rate
for SCD as one of these non-core measures for ORYX requirements
was and is entirely voluntary.
The use of performance measures has evolved. It is notable that
the ORYX initiative initially sought to encourage hospitals to
demonstrate the use of data in improving performance, not for
public reporting or for comparing performance across hospitals. All
of the initial NACHRI proposed ORYX non-core measures were
utilization measures, either length of stay or readmissions, and
geared to high volume pediatric admissions where there might be
sufficient volume to permit pattern analysis. These measures were
not subjected to a scientific validation process and, therefore, we do
not agree with the SCD readmission being listed as a measure of
‘‘accountability’’ in the Quality Measures Compendium compiled
by the Centers for Medicare and Medicaid Services without further
study and validation. Similarly, as it convened an expert panel to
develop a core measure set for children’s asthma care, TJC did not
include proposed readmission measures in the final core set.
As measures are used to compare performance across hospitals,
validation is critical. We agree wholeheartedly with Dr. Quinn that
the ‘‘SCD community needs to critically assess this measurement,’’
and we would further argue that the SCD community should
consider identifying and assessing other measures that best assess
quality of care for these children. Readmission is a subject of
increased interest among policy-makers and payers, and the
professional community should take an active role in validating
measures of quality.
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